Sanofi cuts the cord on collaboration deal with KaloBios

Sanofi Pasteur (SNY +0.5%) (OTCQB:SNYNF) terminates its collaboration and licensing agreement with KaloBios Pharmaceuticals (KBIO -1%) for KB001-A. Sanofi had been developing the monoclonal antibody as a treatment for Pseudomonas aeruginosa ((Pa)) pneumonia prevention while KaloBios was developing it as a treatment for chronic Pa lung infections in cystic fibrosis patients.

Sanofi agreed to terminate in consideration of low single-digit royalties on KB001-A net sales, subject to a $40M cap.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs